Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

company. The company points out that its European summary of product characteristics (SmPC) lists data from APOLLO on primary and secondary endpoints, including exploratory cardiac endpoints - long term data from it ... Alnylam has three more RNAi

UK trumpets life sciences post-Brexit ‘sector deal’

Other projects highlighted in the document include a $100m contract from The Medicines Company to test a cholesterol-lowering drug at the University of Oxford’s clinical trials unit, a £40m ... This ecosystem will deliver for everyone,” he added.

The Medicines Company strengthens board of directors

He said: “ I am delighted to be joining The Medicines Company, especially at such an important time. ... Clive Meanwell, chief executive officer and director of The Medicines Company, said: “We are pleased to welcome someone of Paris’s caliber to

AZ gets EU green light for new antibiotic Zavicefta

The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... The Medicines Company also has a candidate called RPXZ7009 in phase III trials

1 2 3 4 5 [ Next 5 results ]